Literature DB >> 17081917

Complete metastasectomy in patients with stage IV metastatic melanoma.

David W Ollila1.   

Abstract

Patients with stage IV melanoma have traditionally been managed with various systemic treatments; however, overall survival with this approach has been disappointing. Findings of many retrospective, single-institution, and multicentre studies suggest that participants treated with complete metastasectomy for stage IV metastases have enhanced overall 5-year survival. Complete surgical resection of metastatic disease to stage IV sites-including skin, soft tissue, distant lymph nodes, lungs, or other non-CNS visceral regions-offers the best chance for prolonged survival. This Review will present data lending support to the idea that if complete surgical metastasectomy is technically feasible, then surgery should be the first option for properly selected patients with stage IV melanoma.

Entities:  

Mesh:

Year:  2006        PMID: 17081917     DOI: 10.1016/S1470-2045(06)70938-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  29 in total

1.  Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I).

Authors:  J Harrison Howard; John F Thompson; Nicola Mozzillo; Omgo E Nieweg; Harald J Hoekstra; Daniel F Roses; Vernon K Sondak; Douglas S Reintgen; Mohammed Kashani-Sabet; Constantine P Karakousis; Brendon J Coventry; William G Kraybill; B Mark Smithers; Robert Elashoff; Stacey L Stern; Alistair J Cochran; Mark B Faries; Donald L Morton
Journal:  Ann Surg Oncol       Date:  2012-05-31       Impact factor: 5.344

2.  Efficacy of skin-directed therapy for cutaneous metastases from advanced cancer: a meta-analysis.

Authors:  Daniel E Spratt; Elizabeth A Gordon Spratt; Shenhong Wu; Antonio DeRosa; Nancy Y Lee; Mario E Lacouture; Christopher A Barker
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

3.  Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution.

Authors:  Amanda K Raymond; Georgia M Beasley; Gloria Broadwater; Christina K Augustine; James C Padussis; Ryan Turley; Bercedis Peterson; Hilliard Seigler; Scott K Pruitt; Douglas S Tyler
Journal:  J Am Coll Surg       Date:  2011-04-13       Impact factor: 6.113

Review 4.  Surgery and sentinel lymph node biopsy.

Authors:  Mark B Faries; Donald L Morton
Journal:  Semin Oncol       Date:  2007-12       Impact factor: 4.929

5.  Prolonged survival after surgical management of metastases in malignant melanoma: three case reports.

Authors:  S R Whitaker; S J Houston
Journal:  Ann R Coll Surg Engl       Date:  2012-05       Impact factor: 1.891

6.  A 20-year experience of hepatic resection for melanoma: is there an expanding role?

Authors:  Mark B Faries; Anna Leung; Donald L Morton; Danielle Hari; Ji-Hey Lee; Myung-shin Sim; Anton J Bilchik
Journal:  J Am Coll Surg       Date:  2014-05-10       Impact factor: 6.113

Review 7.  Melanoma and nuclear medicine.

Authors:  Andrés Perissinotti; Sergi Vidal-Sicart; Omgo Nieweg; Renato Valdés Olmos
Journal:  Melanoma Manag       Date:  2014-09-05

8.  Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

Authors:  Paolo A Ascierto; Antonio M Grimaldi; Ana Carrizosa Anderson; Carlo Bifulco; Alistair Cochran; Claus Garbe; Alexander M Eggermont; Mark Faries; Soldano Ferrone; Jeffrey E Gershenwald; Thomas F Gajewski; Ruth Halaban; F Stephen Hodi; Richard Kefford; John M Kirkwood; James Larkin; Sancy Leachman; Michele Maio; Richard Marais; Giuseppe Masucci; Ignacio Melero; Giuseppe Palmieri; Igor Puzanov; Antoni Ribas; Yvonne Saenger; Bastian Schilling; Barbara Seliger; David Stroncek; Ryan Sullivan; Alessandro Testori; Ena Wang; Gennaro Ciliberto; Nicola Mozzillo; Francesco M Marincola; Magdalena Thurin
Journal:  J Transl Med       Date:  2014-10-28       Impact factor: 5.531

9.  Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma.

Authors:  Sojun Hoshimoto; Mark B Faries; Donald L Morton; Tatsushi Shingai; Christine Kuo; He-Jing Wang; Robert Elashoff; Nicola Mozzillo; Mark C Kelley; John F Thompson; Jeffrey E Lee; Dave S B Hoon
Journal:  Ann Surg       Date:  2012-02       Impact factor: 12.969

10.  A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Mortality of Patients with Initially Diagnosed Metastatic Cutaneous Melanoma.

Authors:  Wei Li; Yang Xiao; Xuewen Xu; Yange Zhang
Journal:  Ann Surg Oncol       Date:  2020-11-15       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.